About Eisai China


Eisai is a multinational company specializing in the research and development of pharmaceutical products, headquartered in Tokyo and founded in 1941. Its overseas branches, subsidiaries and factories are located in Europe, the Americas and Asia, with a total capitalization of 44,986 million yen and a global workforce of more than 10,000 employees. In FY2022, Eisai reached 744 billion yen (approximately RMB 38 billion) globally, with an investment of 173 billion yen (approximately RMB 8.8 billion) in research and development (R&D).

Since Eisai entered the Chinese market in the early 1990s, it has been developing smoothly, establishing Shenyang Eisai Pharmaceutical Co., Ltd. in 1991 and Eisai (Suzhou) Pharmaceutical Co., Ltd. in 1996, and then it officially renamed  to Eisai China Inc. in 2002. Along with the development of its business in China, now its member companies include Eisai China Holdings Ltd., Eisai China Inc., Eisai (Liaoning) Pharmaceutical Co., Ltd., Eisai (Suzhou) Trading Co., Ltd., Eisai (Hong Kong) Co., Ltd., and it established a joint-venture company “Unlimit Health Limited.”

At present, the total registered capital in China is US$108.54 million, and its HQ in China is located in Shanghai. Eisai China has formed a scale of development to sell dozens of pharmaceuticals in China, focusing on the fields of NTA, Oncology (Special Care), GI, etc., and expanding the field of generic drugs and Internet+medicine files. Eisai China is ranked 17th of global multinational pharmaceutical companies in China in 2022.